Purchase this article with an account.
Thomas A Aller; Myopia progression before and after fitting with the NaturalVue multifocal contact lens – a case series analysis. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4770.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Myopia progression control has been shown with distance center multifocal contact lenses. One study has shown myopia progression control with the NaturalVue Multifocal, (Visioneering Technologies, Inc, Alpharetta GA), a novel distance center, extended depth of focus lens. We performed a retrospective, observational clinical trial of the rates of myopic progression in a series of young patients before and after switching to this design.
The right eyes of all consecutive patients (n=26) with progressing myopia in either eye who chose to be fitted with the NaturalVue lens were included in this analysis. Refractive data are the average spherical equivalent subjective refraction. Axial lengths are measured by the Zeiss IOLMaster. All rates are adjusted to six-month rates.
Average age was 11.83 ± 3.63 years (6.97 to 22.27). 69% were female, and 31% were male. Eleven patients wore single vision spectacles or were uncorrected prior to being refit, while the others wore multifocal contacts (n=7), multifocal contacts plus atropine (n=3), bifocals or PALS (n=2), orthokeratology (n=2) and one patient used atropine only. Pre-fit myopic progression measured over an average of 1.20 years ranged from 0.0 D to -2.50 D, with an average of -0.89 ± 0.71 D. Adjusted to a six-month rate, the average was -0.45 D ± 0.42 D. Rates of myopia progression adjusted to six-month rates post-fit ranged from -0.72 D to 0.57 D, with an average progression of 0.00 ± 0.30 D. This represents an average 100% reduction in myopic progression after wearing the NaturalVue Multifocal lenses. Axial length rates for the 11/25 patients with data during both phases, averaged 0.13 mm ± 0.08 mm, reducing to 0.07 mm ± 0.07 mm, representing a 45% reduction in axial elongation. Interestingly, the 15 patients using myopia control prior reduced from -0.23 D ± .19 D to -0.01 D ± 0.22 D with the study lens. All differences between groups were found to be highly statistically significant with a paired samples t-test (p<0.001). No adverse events were observed and no child discontinued wear of the lenses.
A clinically significant reduction in myopia progression and axial elongation was observed when switching patients to the NaturalVue Multifocal, offering further evidence that these extended depth of focus, distance center multifocal contact lenses may be an effective treatment for myopia progression.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only